Health-related non-profit research funding

If you plan to apply for funds...

Please let the indicated Office of Research contact know of your plans to apply as soon as possible. If application review is desired and/or institutional sign-off is required, please provide an electronic copy of your application two weeks prior to the submission deadline.

Note that the Office of Research can assist applicants seeking partnerships (e.g. for applications that require matching funds).

Funding opportunities

Canadian institutions are eligible to apply for all opportunities listed below. The quick list of new opportunities hyperlinks to details. Previously announced and ongoing opportunities follow the detailed list. All details were accurate at time of posting but are susceptible to changes by the sponsor. Always check the sponsor's website for current deadline date. NEW – we now have a separate listing for NIH opportunities following the ongoing opportunities.


New Opportunities (as of 25 June 2021)

Sponsor Quick List

American Association for Cancer Research – various
CURE Epilepsy Catalyst Award
North American Neuroendocrine Tumor Society Research Grants
Alzheimer Society Research Program: Proof of Concept Research Grant
OICR Cancer Therapeutics Innovation Pipeline
Public Health Agency of Canada (PHAC): The Intersectoral Action Fund
CCS Challenge Grants
Genome Canada: Genomic Applications Partnership Program (GAPP)
Merck KGaA Germany: Biopharma Speed Grant
Canadian Glycomics Network (GlycoNet): International Partnerships

Details

American Association for Cancer Research
Contact: Lisa Sergovich

  • AACR-MPM Oncology Charitable Foundation Transformative Cancer Research Grants: This novel grant mechanism is intended to promote and support creative, paradigm-shifting cancer research that might not be funded through conventional channels. The proposed research must represent a highly innovative approach to a major problem or challenge in cancer research. The funded projects are expected to catalyze important advances in cancer research and should have a potentially transformative impact on future clinical practice. The research can be in any area of basic, translational, or clinical research. LOI Deadline: June 29, 2021, 1 PM EDT. Application Deadline: September 30, 2021, 1 PM EDT.
  • AACR-The Mark Foundation for Cancer Research “Science of the Patient” (SOP) Grants: This program represents a joint effort to stimulate novel research aimed at understanding the influence of the biology of the host (i.e., patient) on the genesis, development, treatment, and survivorship of cancer. Successful projects should emphasize the interplay of host physiological systems with the tumor and/or tumor microenvironment. The proposed research must represent a highly innovative approach to a major problem or challenge in cancer research, with an emphasis on understanding the influence of the biology of the host on the genesis, development, treatment, and sequelae of cancer. The funded projects are expected to catalyze important advances in the field and should have a potentially transformative impact on future clinical practice. LOI Deadline July 13, 2021, 1 PM EDT. Application Deadline: November 4, 2021, 1 PM EDT.

CURE Epilepsy Catalyst Award
Contact: Lisa Sergovich
This award supports nimble development of data necessary to advance ideas toward larger commercialization funding opportunities and is not intended to replace those opportunities. LOI Deadline: June 30, 2021, 9 PM ET.

North American Neuroendocrine Tumor Society Research Grants
Contact: Lisa Sergovich
This year, NANETS is pleased to offer two research grants to support innovative research initiatives and encourage young researchers and scientific clinicians to become NET specialists in the following areas: Basic/Translational Science, Clinical Investigation, and Theranostics. Application Deadline: July 2, 2021, 11:59 PM PT.

Alzheimer Society Research Program: Proof of Concept Research Grant
Contact: Lisa Sergovich
This grant is meant to fund established researchers with big, bold, outside-the-box ideas relevant to Alzheimer’s disease and other dementias who are conducting innovative, high-risk and high-reward approaches to dementia research. Existing hypotheses are not encouraged to be submitted. LOI Deadline: July 6, 2021.

OICR Cancer Therapeutics Innovation Pipeline
Contact: Lisa Sergovich
This program was established to capitalize on Ontario’s expertise in cancer biology and drug discovery to create a pipeline of validated cancer targets and first-in-class or best-in-class, novel, selective lead molecules (small molecules or biologics) that would attract partnerships and/or investment for further preclinical and clinical development. To generate a sustainable pipeline, CTIP will support projects that aim to provide increasing evidence of target validation and disease association using functional assays and drug screening in relevant in vitro and in vivo models of the cancer type of interest. View website for details on the available funding streams. Notice of Intent and LOI Deadline: July 7, 2021, 5 PM ET. Full Application Deadline: September 15, 2021, 5 PM ET.

Public Health Agency of Canada (PHAC): The Intersectoral Action Fund
Contact: Lisa Sergovich
Intersectoral action refers to the ways that different groups and sectors of society work together to improve health and the conditions that shape health. Under the Intersectoral Action Fund, the Public Health Agency of Canada is seeking proposals for community-based projects that support collective action on the social determinants of health. Specifically, this solicitation will aim to build capacity for intersectoral action across three project Streams: Stream 1 – Identify priority areas for collective action on social determinants of health and wellbeing, Stream 2 – Foster transformative partnerships to facilitate action on social determinants of health and wellbeing, and Stream 3 – Build capacity to take action on social determinants of health and wellbeing. If you are interested in applying to this funding opportunity, please email phac.cgc.solicitations-csc.aspc@canada.ca and reference “Intersectoral Action Fund” in the subject line to request an application package. Only Funding Requests using the template provided in the application package will be considered. Application Deadline: July 12, 2021, 3 PM EDT.

CCS Challenge Grants
Contact: Lisa Sergovich
The Canadian Cancer Society (CCS) is proud to launch a new funding program in support of cancer research across Canada. The Challenge grant program will support cancer research projects across the cancer continuum and across disciplines, with an ultimate goal of solving a problem (i.e. a ‘challenge’) in cancer that will be meaningful to people affected by or at risk of cancer. Applications for up to $150,000 per year for 3 years will be accepted. The approximate funding envelope for this competition is $5.25M per year, or enough to fund at least 35 grants. Applications focused on breast cancer and prostate cancer are encouraged. Abstract Registrations Deadline: July 28, 2021. Full Application Deadline: September 22, 2021.

Genome Canada: Genomic Applications Partnership Program (GAPP)
Contact: Lisa Sergovich
The GAPP aims to: Accelerate the application of Canadian genomics-derived solutions from academia to real-world opportunities and challenges defined by industry, not-for-profit and public-sector Receptors; Channel Canada’s genomics capacity into sustainable innovations that benefit Canadians; Enhance the value of Canadian genomics technologies by de-risking and incentivizing follow-on investment from industry and other partners; and Foster mutually beneficial collaboration and knowledge exchange between Canadian academia and technology receptors. View website for more details about funding and eligibility. EOI Deadline: August 10, 2021.

Merck KGaA Germany: Biopharma Speed Grant
Contact: Ibi Brown and Regan Child
Merck KGaA, Darmstadt, Germany, is dedicated to accelerating innovation and advancing science. That’s why they want to foster independent research by reducing financial hurdles for researchers. Pre-clinical researchers in the fields of oncology, immuno-oncology, autoimmune disorders and drug discovery technologies are invited to apply to this fast funding program: the Biopharma Speed Grant Initiative. There is no application deadline; applications can be submitted at any time.

Canadian Glycomics Network (GlycoNet): International Partnerships
Contact: Lisa Sergovich
GlycoNet has formalized a partnership with Academia Sinica to co-fund collaborative research between two entities. These grants fund projects that involve at least two groups, one in Canada and one in Taiwan. GlycoNet will fund research conducted in Canada, while Academia Sinica will fund research conducted in Taiwan. Projects require at least a 1:1 matching and must be completed within 12 months. Accepted on a rolling basis.

Previously Announced

Sponsor Quick List

Canadian Cancer Society: Impact Grant
Simons Foundation: Genomics of Autism Spectrum Disorders: Pathways to Genetic Therapies
Heart Failure Research Network
Alex’s Lemonade Stand Foundation – various
Canadian Blood Services – various
Canadian Glycomics Network (GlycoNet) – various
Merck KGaA: 2021 Research Grants
Ontario Women's Health Scholars Awards
Complementary Medicine Field Bursary

Details

Canadian Cancer Society: Impact Grant
Contact Lisa Sergovich
The Impact Grant program supports significant progression in cancer research programs that are anywhere in the continuum from basic, high impact discovery to translational work of direct relevance to the clinic, to applied research. Impact Grants aim to accelerate and focus the knowledge gained from scientific findings, in the short- to medium-term, into outcomes that will significantly improve scientific knowledge relevant to cancer, result in improved cancer treatment, result in optimized care of people living with and beyond cancer, and result in reduced cancer burden. Budgets awarded will not exceed $300,000 per year, to a maximum of $1,500,000 per grant. The grant term is up to 5 years. Grants will be renewable at the end of their term.  Letter of Intent Deadline: April 29, 2021 (NOW POSTPONED). Application Deadline: TBD.

Simons Foundation: Genomics of Autism Spectrum Disorders: Pathways to Genetic Therapies
Contact: Lisa Sergovich
Proposals should be in three broad areas of ASD genomics: (1) risk gene discovery and systems biology, (2) functional analysis of variants associated with ASD risk genes and (3) gene-targeted therapies. Successful proposals with a focus on the first two areas will likely involve large-scale analyses. View website for specific details and eligibility. Deadline: July 6, 2021.

Heart Failure Research Network
Contact: UW CIHR
CIHR has recently launched a $5M funding opportunity to support a single nationally coordinated, interdisciplinary heart failure research network. The goal of the Network is to understand the underlying causes, pathophysiology and social determinants of heart failure and to improve the prevention, detection, management, patient outcomes, quality of life, and delivery of care of this common and multifactorial condition. This funding opportunity is created in partnership with Heart & Stroke, Mitacs, and National Institutes of Health – National Heart, Lung, and Blood Institute (NIH-NHLBI). Registration deadline: July 7, 2021. Application Deadline December 7, 2021.

Alex’s Lemonade Stand Foundation
Contact Lisa Sergovich
2021 Young Investigator Grant
: This is a mentored career development award designed to support early career researchers, such as postdoctoral fellows, clinical fellows or instructors, striving to develop independent careers in pediatric cancer research. A mentor is required, and a career development plan must be included. The budget for this award is $150,000 over three years. Review guidelines on the website. Deadline: July 12, 2021 by 8p, ET.

Canadian Blood Services
Contact: Lisa Sergovich

  • Canadian Blood Services Postdoctoral Fellowship Program: through its Postdoctoral Fellowship Program, Canadian Blood Services offers salary support for young investigators. Postdoctoral fellows undertaking full-time research training in a Canadian research laboratory affiliated with Canadian Blood Services are invited to apply. The fellowship provides salary support plus benefits, and a one-time research allowance of $20,000. Fellows may be supported for a maximum of three years. Deadline: July 15, 2021.
  • Blood Efficiency Accelerator Program: the objective of this program is to improve the efficient and appropriate utilization of blood products, while maintaining the safety of the blood system. To achieve this objective, the Program will support innovative research projects that seek new knowledge or accelerate the application of existing knowledge. Deadline: July 15, 2021.

Canadian Glycomics Network (GlycoNet)
Contact Lisa Sergovich

  • Clinical Partnerships: offer clinicians and biomedical researchers opportunities to partner with Network Investigators to study glycans or glycosylation changes in disease. This partnership would increase clinician awareness of the role of glycomics in disease, and expand glycomics translational research and its application in more problems of clinical importance. Partnership outcomes could be better understanding of disease, drug development strategies, or new drug targets. Deadline: August 31, 2021.
  • Translational Grants: areas of focus are neurogenerative diseases, infectious diseases, chronic diseases, in particular diabetes & obesity, genetic diseases involving errors in glycan metabolism, and cancer. A key goal of GlycoNet is the translation of research advances into novel products for treating disease. This Request for Proposals seeks to fund more mature projects needing Network support to de-risk and advance them to a state at which translation is possible. Deadline: August 31, 2021.
  • Strategic Initiatives: areas of focus are neurogenerative diseases, infectious diseases, chronic diseases, in particular diabetes & obesity, genetic diseases involving errors in glycan metabolism, and cancer. A key goal of GlycoNet is the translation and commercialization of research advances. This Request for Proposal seeks to fund partner-led projects that address needs of the pharmaceutical of biotechnology industry. Deadline: August 31, 2021.

Merck KGaA: 2021 Research Grants
Contact: Michele Van Dyke
This year Merck KGaA is offering research grants of 40k€ - 450k€ per year for up to 3 years in the areas of: drug discovery, real time testing and sensors, nanoparticles for nucleic acid delivery, digital innovation, bioelectronics, sustainability, media recycling for cultured meat, organoids. Deadline: August 31, 2021.

Ontario Women's Health Scholars Awards
Contact Lisa Sergovich
Funded by the Ontario Ministry of Health and Long-Term Care, a Scholar Awards Program in Women's Health has been established to ensure that Ontario attracts and retains pre-eminent women's health scholars. The community of women's health scholars fostered by this Awards program will excel, according to internationally accepted standards of scientific excellence, in the creation of new knowledge about women's health and its translation into improved health for women, more effective health services and products for women, and a strengthened heath care system. View website for eligibility details. Deadline: December 1, 2021.

Complementary Medicine Field Bursary
Contact Lisa Sergovich
The purpose of this bursary scheme is to ensure that reviews relevant to complementary, alternative and integrative medicine (CAM) are completed and published in the Cochrane Library. The bursary scheme funds are to be used either to help support the conversion of a CAM-related Cochrane protocol into a full Cochrane review or to help support an update of an existing Cochrane review. Deadline: December 18, 2021.


 

ONGOING OPPORTUNITIES

Sponsor Quick list

Alzheimer’s Drug Discovery Foundation
BioCanRx: Canada’s Immunotherapy Network
Crohn’s and Colitis Foundation (US)
Max Bell Foundation
Thrasher Research Foundation (US)
T.R. Meighen Family Foundation
Early Phase Clinical Trials:Canada
Rising Tide Foundation: Freedom in Practice & Cancer Research

Details

Alzheimer’s Drug Discovery Foundation
Contact Lisa Sergovich (519-888-4567, ext. 36033)
ADDF has regular RFP for projects that align with the core areas of the sponsor: drug discovery; clinical trials; biomarkers; prevention. The ADDF is interested in novel therapeutic approaches, including small molecules, biologics, and gene therapies. Because the mechanisms underlying Alzheimer's disease and related dementias are varied and complex, the sponsor maintains a diverse portfolio of drug targets.

BioCanRx: Canada’s Immunotherapy Network
Contact Lisa Sergovich (519-888-4567, ext. 36033)
BioCanRx invites researchers and their teams to participate in its open, rolling research funding call. The open call builds on past and ongoing investments in the area of cancer biotherapeutics and aims to strengthen Canada’s ability to develop this emerging and promising area of cancer research.

Crohn’s and Colitis Foundation (US)
Contact Lisa Sergovich (519-888-4567, ext. 36033)
The Crohn’s & Colitis Foundation is a leading funder of basic and clinical research in inflammatory bowel diseases (IBD), or Crohn's disease and ulcerative colitis. The Foundation supports research that increases understanding of the etiology, pathogenesis, therapy, and prevention of these diseases. In addition to supporting studies and clinical trials, the Foundation provides grants and fellowships for the training and development of the next generation of researchers and physicians specializing in IBD. Since its founding in 1967, the Foundation has awarded thousands of IBD grants totaling approximately $330 million of funding invested in research. All grant applicants must submit their proposal via online forms (Proposal Central System) found on each opportunity page.

Max Bell Foundation
Contact Lisa Sergovich (519-888-4567, ext. 36033)
The sponsor encourages the development of innovative ideas that impact public policies and practices with an emphasis on health and wellness, education, and the environment. Max Bell Foundation provides support with three types of grants: Project Grants, Development Grants, and Senior Fellow Grants.

Thrasher Research Foundation (US)
Contact Lisa Sergovich (519-888-4567, ext. 36033)
E. W. “Al” Thrasher Awards: The Thrasher Research Fund has been awarding grants for children's medical research for over 40 years. The purpose of the E.W. "Al" Thrasher Awards is to improve children's health through medical research, with an emphasis on​ projects that have the potential to translate into clinically meaningful results within a few years. The Fund awards grants two times per year, with no fixed number of awards given in each funding cycle or in each year. Application Deadline: Rolling Acceptance

T.R. Meighen Family Foundation
Contact Lisa Sergovich (519-888-4567, ext. 36033)
The T.R. Meighen Family Foundation supports strategic and creative initiatives that benefit communities and their most vulnerable members, primarily in Toronto and New Brunswick. Areas of interest include but are not limited to education, health, social welfare, cultural and environmental conservation.  Letter of inquiry may be submitted any time

Early Phase Clinical Trials: Canada
Contact Lisa Sergovich (519-888-4567, ext. 36033)
The Early Phase Clinical Trials: Canada program was created to provide funding support for clinical trials and clinical trial sub-studies with excellent preliminary data.  Applications focused on complementary approaches (e.g., diet, physical activity, sleep, speech therapy, cognitive therapy) are eligible for the Early Phase Clinical Trials program, if they meet the other program scope criteria and have specific supportive evidence/justification (from published literature or unpublished data) to warrant further investigation. Please refer to the Institute’s definitions on complementary approaches for more details.

Rising Tide Foundation: Freedom in Practice & Cancer Research
Contact Lisa Sergovich
Once you have submitted your LOI you will receive further information regarding the timing and next steps. Our board meetings take place in May, August, and December. The evaluation period is between 3 and 6 months. If your project meets our funding criteria, we will contact you and extend an invitation for you to submit a full grant application for further consideration. If you are uncertain about the eligibility of your proposal, please email us at grants@risingtide-foundation.org before beginning an application, or download information on our funding criteria.

National Institutes of Health (US)

National Institutes of Health (US)

Contact Christina Kroeker (519-888-4567, ext. 37123)

Please visit the NIH website for more information on upcoming opportunities.

Ongoing Parent Funding Opportunities Submission Deadline Submission Type

Research Project Grants (R01)

multiple until May 8, 2023  

Exploratory/Developmental Research Grants (R21)

multiple until May 8, 2023  

Small Research Grants (R03)

multiple until May 8, 2023  
Notices of Special Interest (selected and newly released) Submission Deadline

Submission Type
Please contact Christina Kroeker institutional guidance

Aging-Relevant Behavioral and Social Research on Coronavirus Disease 2019 (COVID-19) May 8, 2023 Application
COVID-19 Related School Disruptions Impact on Mental Health, Cognitive, Social, and Emotional Development of Children September 8, 2022 Application
Leveraging Real-World Imaging Data for Artificial Intelligence-based Modeling and Early Detection of Abdominal Cancers January  8, 2024 Application
NIH Research Project Grant (R01) Applications from Individuals from Diverse Backgrounds, Including Under-Represented Minorities May 8, 2023 Application
Public Policy Effects on Alcohol-, Cannabis-, Tobacco-, and Other Drug-Related Behaviors and Outcomes September 8, 2024 Application
Understanding the effects of cancer and cancer treatment on aging trajectories and aging outcomes January  8, 2024 Application
Effects of smoking and vaping on the risk and outcome of COVID-19 infection September  8, 2024 Application
High-Priority Interest to Enhance Data Science Research Training in Addiction Research December 9, 2024 Application
Secondary Analysis of Existing Datasets for Advancing Immune-mediated and Infectious Disease Research May 8, 2024 Application

Strategic Grants (selected)

R01 = Research Project GrantR21/R23 =Developmental/Exploratory Grant

Submission Deadline

Submission Type

LOI may be due 30 days prior

Behavioral & Integrative Treatment Development Program (R01 Clinical Trial Optional)

Multiple until March 23, 2022 Application
Bioengineering Research Grants (BRG) (R01 Clinical Trial Required) May 8, 2022 Application
BRAIN Initiative: Development and Validation of Novel Tools to Probe Cell-Specific and Circuit-Specific Processes in the Brain (R01 Clinical Trial Not Allowed) October 7, 2023 Application
BRAIN Initiative: Integration and Analysis of BRAIN Initiative Data (R01 Clinical Trial Not Allowed) Multiple until June 7, 2024 Application

Cellular and Molecular Biology of Complex Brain Disorders (R01)

Multiple until September 8, 2023

Application
BRAIN Initiative: Proof of Concept Development of Early Stage Next Generation Human Brain Imaging (R01 Clinical Trial Not Allowed) September 4, 2021 Application
BRAIN Initiative: Secondary Analysis and Archiving of BRAIN Initiative Data (R01 Clinical Trial Not Allowed) October 7, 2021 Application
**NEW** BRAIN Initiative: New Technologies and Novel Approaches for Recording and Modulation in the Nervous System (R01 Clinical Trial Not Allowed) Multiple until October 27, 2023 Application

Ethical, Legal and Social Implications (ELSI) (Research R01 Clinical Trial Optional)

Multiple until June 19 2023 Application
**NEW** High Resolution Mapping of Biomolecules in Brain Cells in Aging and Alzheimer’s Disease (R01 Clinical Trial Not Allowed) October 29, 2021 Application

Innovative Research in Cancer Nanotechnology (IRCN) (R01 Clinical Trial Not Allowed)

Multiple until May 4, 2023 Application
Modular R01s in Cancer Control and Population Sciences (R01 Clinical Trial Optional) Multiple until March 7, 2024 Application

NIDCD Low Risk Clinical Trials in Communication Disorders (R01 Clinical Trial Required)

Multiple until January 8, 2024 Application

Novel Mechanism Research on Neuropsychiatric Symptoms (NPS) in Alzheimer's Dementia (R01 Clinical Trial Optional)

Multiple until May 8, 2023 Application

Novel Synthetic Nucleic Acid Technology Development (R01 Clinical Trial not allowed)

Multiple until February 4, 2022 Application

Research Projects to Enhance Applicability of Mammalian Models for Translational Research (R01 Clinical Trial Not Allowed)

Multiple until May 8, 2023 Application

Secondary Analysis and Integration of Existing Data to Elucidate the Genetic Architecture of Cancer Risk and Related Outcomes (R01 Clinical Trial Not Allowed)

Multiple until September 8, 2022

Application
**NEW** Systems Approach to Understand Mechanisms of Heterogeneous Response to Influenza (R01 Clinical Trial Not Allowed) September 9, 2021 Application

Translational Bioinformatics Approaches to Advance Drug Repositioning and Combination Therapy Development for Alzheimers Disease (R01 Clinical Trial Optional)

Multiple until May 8, 2023 Application

Translational Research in Maternal and Pediatric Pharmacology and Therapeutics (R01 Clinical Trial Optional)

Multiple until December 9, 2022 Application
Exploratory/Developmental Research Grants (R21) (selected) Submission Deadline Submission Type

Catalytic Tool and Technology Development in Kidney, Urologic and Hematologic Diseases (R21 Clinical Trial Not Allowed)

Multiple until May 8, 2023 Application

Cellular and Molecular Biology of Complex Brain Disorders (R21 Clinical Trial Not Allowed)

Multiple until September 8, 2023

Application

Ethical, Legal and Social Implications (ELSI) (R21) (Clinical Trial Optional)

Multiple until June 19 2023 Application
Maximizing the Scientific Value of Existing Biospecimen Collections (R21 Clinical Trial Not Allowed) Multiple until March 9, 2023 Application
NIH Blueprint for Neuroscience Research: Tools and Technologies to Explore Nervous System Biomolecular Condensates (R21 Clinical Trial Not Allowed) September 15, 2021 Application with LOI due 30 days prior
Novel Synthetic Nucleic Acid Technology Development (R21 Clinical Trial not allowed) Multiple until June 24, 2022 Application

Secondary Analysis and Integration of Existing Data to Elucidate the Genetic Architecture of Cancer Risk and Related Outcomes (R21 Clinical Trials Not Allowed)

Multiple until September 8, 2022

Application
Secondary Analyses of Existing Datasets of Tobacco Use and Health (R21 Clinical Trial Not Allowed) Multiple until March 9, 2023 Application
Research Project - Co-operative Agreements (U01) (selected) Submission Deadline Submission Type

**NEW** BRAIN Initiative: Optimization of Transformative Technologies for Recording and Modulation in the Nervous System (U01 Clinical Trials Not Allowed)

Multiple until October 27, 2023 Application
Other Submission Deadline Submission Type

Back to Top